IgA Nephropathy News and Research

RSS

IgA nephropathy (IgAN), also known as Berger’s disease, is the leading cause of primary glomerulonephritis all over the world. It is autoimmune in origin, characterized by the stimulation of genetically determined formation of concentration of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1) in the blood. These stimulate anti-glycan antibody production, followed by binding with the aberrantly glycated IgA1.

Steroid treatment can delay loss of kidney function

For patients with IgA nephropathy, a type of kidney disease, steroid treatment can prevent or delay loss of kidney function, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). IgA nephropathy is an autoimmune disease that affects the kidneys and a major cause of end-stage kidney failure in younger people

16 Jul 2010

PIKAMAB secures exclusive rights to issued U.S. patent from UABRF

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has secured exclusive rights to an issued U.S. patent (US 6,986,987) from the UAB Research Foundation. This patent pertains to the discovery that the functional polymorphism (Ser/Gly248) in the cytoplasmic domain of Fc alpha receptor determines the proinflammatory potential of serum IgA autoantibodies through cell signaling and production of cytokines such as TNF-alpha, IL-6, and IL-1β in an allele-dependent manner.

1 Jul 2010

BioMarin Pharmaceutical reports GAAP net income of $4.7M for fourth-quarter 2009

BioMarin Pharmaceutical Inc. today announced financial results for the fourth quarter and year ended December 31, 2009. GAAP net income was $4.7 million ($0.05 per diluted share) for the fourth quarter of 2009, compared to GAAP net income of $24.5 million ($0.21 per diluted share) for the fourth quarter of 2008, which included a $30.0 million payment from Merck Serono related to the approval of Kuvan in the EU.

24 Feb 2010

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

Omega-3 fatty acids ineffective for managing Crohn's disease

An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn's disease.

9 Apr 2008

ACE inhibitors help preserve kidney function in IgA nephropathy

For young patients with the kidney disease IgA nephropathy (IgAN), early treatment with angiotensin-converting enzyme (ACE) inhibitors can reduce the long-term risk of irreversible kidney damage, suggests a study in the June Journal of the American Society of Nephrology.

17 May 2007